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ABSTRACT 
Fungi cause serious life-threatening infections in immunocompromised individuals and current 
treatments are now complicated by toxicity issues and the emergence of drug resistant strains. 
Consequently, there is a need for development of new antifungal drugs. Inosine 
monophosphate dehydrogenase (IMPDH), a key component of the de novo purine biosynthetic 
pathway, is essential for growth and virulence of fungi and is a potential drug target. In this 
study, a high-throughput screen of 114,000 drug-like compounds against Cryptococcus 
neoformans IMPDH was performed. We identified three 3-((5-substituted)-1,3,4-oxadiazol-2-
yl)thio benzo[b]thiophene 1,1-dioxides that inhibited Cryptococcus IMPDH and also possessed 
whole cell antifungal activity. Analogs were synthesized to explore the SAR of these hits. 
Modification of the fifth substituent on the 1,3,4-oxadiazole ring yielded compounds with 
nanomolar in vitro activity, but with associated cytotoxicity. In contrast, two analogs generated 
by substituting the 1,3,4-oxadiazole ring with imidazole and 1,2,4-triazole gave reduced 
IMPDH inhibition in vitro, but were not cytotoxic. During enzyme kinetic studies in the 
presence of DTT, nucleophilic attack of a free thiol occurred with the benzo[b]thiophene 1,1-
dioxide. Two representative compounds with substitution at the 5 position of the 1,3,4-
oxadiazole ring, showed mixed inhibition in the absence of DTT. Incubation of these 
compounds with Cryptococcus IMPDH followed by mass spectrometry analysis showed non-
specific and covalent binding with IMPDH at multiple cysteine residues. These results support 
recent reports that the benzo[b]thiophene 1,1-dioxides moiety as PAINS (pan-assay 
interference compounds) contributor. 
Keywords: High-throughput screening; IMPDH inhibitor; antifungal; PAINS; mass 
spectrometry; Cryptococcus neoformans. 
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1. Introduction 
The Fungal Infection Trust has estimated that approximately 300 million people worldwide are 
afflicted with serious fungal infections.1 Many of these pathogenic fungi are opportunistic and 
infect when the human immune system is compromised due to HIV/AIDS, anticancer 
chemotherapy or immunosuppressant treatment during organ transplantation. Aspergillus 
fumigatus, Candida albicans and Cryptococcus neoformans are among the most common 
fungal pathogens and are associated with highest mortality rates in immunocompromised 
populations.2,3 
 
According to the Center for Disease Control and Prevention, nearly 220,000 new cases of 
cryptococcal meningitis occur each year with a fatality rate of >50%.4 Cryptococcus infection 
occurs via inhaled spores that cause pulmonary infection in the lung alveoli. Later, the infection 
spreads to other parts of the body. Fungal cells that cross the blood brain barrier infect the 
meningeal membrane that protects the spinal cord and the brain. Resulting inflammation of the 
meninges causes cryptococcal meningitis, which is fatal unless treated.5,6 The recommended 
treatment for cryptococcal meningitis is a combination antifungal therapy that uses 
amphotericin B deoxycholate and flucytosine, which is followed by life-long maintenance 
therapy with fluconazole to prevent reinfection. Amphotericin B therapy is associated with 
nephrotoxicity and infusion-related reactions such as chest pain, dyspnea, hypoxia, flushing, 
and urticaria.7 Flucytosine and fluconazole cause adverse gastrointestinal effects and are toxic 
to bone marrow.8,9 Moreover, the increasing resistance acquired by C. neoformans is making 
available treatments less effective. Given the limitations of existing antifungal therapeutics, 
there is a need to consider new approaches and targets.10 
One such potential target is inosine monophosphate dehydrogenase (IMPDH), an enzyme of 
the purine metabolic pathway. IMPDH forms a homotetramer that catalyses the two-step 
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conversion of inosine-5′-monophosphate (IMP) to xanthosine-5′-monophosphate (XMP) using 
nicotinamide adenine dinucleotide (NAD) as a cofactor (Figure 1).11 Deletion of the IMD1 
gene encoding IMPDH in C. neoformans leads to guanine auxotrophy and virulence factor 
production defects. Moreover, the mutant was avirulent in two animal infection models.12 
While C. neoformans is susceptible to the human IMPDH inhibitor mycophenolic acid (MPA), 
this well-known drug also targets the human IMPDH isoforms as an immunosuppressant. In 
treating immunocompromised individuals, the immunosuppressant properties of known 
IMPDH inhibitors, such as MPA, would clearly be detrimental to health and therefore 
discovery of fungal specific IMPDH inhibitors is essential. Both the crystal structure of 
Cryptococcus IMPDH, and kinetic data have revealed significant differences between this 
fungal enzyme and its human counterparts, providing an opportunity to produce novel, species-
specific inhibitors.12 
 
Figure 1. Two step mechanism for the conversion of IMP to XMP catalysed by IMPDH. 
In this study, we highlight a set of inhibitors of Cryptococcus IMPDH identified using an 
enzyme inhibition assay adapted for high-throughput screening conducted with 114,000 drug-
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like compounds from the Walter and Eliza Hall Compound Collection. Out of the screening, a 
hit-set of three molecules was identified comprising 1,3,4-oxadiazole ring attached to a 
benzothiophene-1,1-dioxide moiety via thioether group linkage. In addition to their unique 
structure and under-explored biological activity, they had potent inhibitory activity against 
Cryptococcus IMPDH and significant antifungal activity. Fifteen analogs were synthesized by 
modification of the aromatic group at the fifth position of the 1,3,4-oxadiazole ring moiety, to 
find selective Cryptococcus IMPDH inhibitors with potent antifungal activity. The observed 
IC50 values against Cryptococcus IMPDH were consistent across all synthesized compounds 
and displayed potent antifungal activity. Modification of the 1,3,4-oxadiazole ring to imidazole 
or 1,3,4-triazole led to the loss of Cryptococcus IMPDH inhibition and antifungal activity. 
Mass spectrometry studies of Cryptococcus IMPDH incubated with one of the compounds 
showed nucleophilic attack of the cysteine thiolate anion at the C3-position of 
benzo[b]thiophene 1,1-dioxide. This reactivity also caused compound breakdown when 
performing kinetics studies in the presence of dithiothreitol (DTT). Consistent with our 
findings, Dahlin et al., recently reported that benzo[b]thiophene 1,1-dioxides were assay 
interfering compounds (PAINS).13-16  
2. Results and discussion 
2.1. Chemistry 
To identify inhibitors of Cryptococcus IMPDH, the Walter and Eliza Hall Compound 
Collection (114,000 drug-like compounds) was screened using a spectrophotometric assay to 
measure the amount of NADH produced by IMPDH enzymatic activity. A 3-((5-substituted)-
1,3,4-oxadiazol-2-yl)thio benzo[b]thiophene 1,1-dioxide series of hits was identified, with IC50 
values between 1 and 2 µM. On the basis of in silico docking studies to improve enzyme 
inhibition and antifungal activity, substitution at position 5 of the 1,3,4-oxadiazole ring was 
investigated. The synthetic route involved coupling 5-substitued 1,3,4-oxadiazole-2-thiol 
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intermediates with 3-bromo benzo[b]thiophene 1,1-dioxide (2) with copper iodide catalyst and 
benzotriazole under basic conditions (potassium tert-butoxide or Cs2CO3) in DMSO. These 
conditions had not previously been investigated with heteroaromatic thiols but afforded the 
desired compounds 5a-5o in good yields (Scheme 2).17 The N-acetyl modified compound 5o 
was synthesized from compound 5n by acetylation of amino groups using acetyl chloride and 
Et3N as the base, in THF as the solvent. 
 
Scheme 1. Synthetic route of intermediate 2. Reagents and conditions: (i) m-CPBA, DCM, rt 
3-Bromo benzo[b]thiophene 1,1-dioxide (2) was synthesized by oxidization of commercially 
available 3-bromo benzo[b]thiophene (1) using m-CPBA (Scheme 1). Required 5-substitued 
1,3,4-oxadiazole-2-thiol intermediates were purchased commercially or synthesized by 
cyclization of the respective acid hydrazide using carbon disulfide in DMF, as reported by 
Mohammad Soleiman-Beigi et al. (Scheme 2).18 However, an alternative method was needed 
to cyclize the cyclohexane carbohydrazide (3e) using carbon disulfide in ethanol, followed by 
addition of potassium hydroxide to give 5-(cyclohexyl)-1,3,4-oxadiazole-2-thiol (4e).19,20 
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Scheme 2. Synthetic route of final compounds. Reagents and conditions: i) CS2, DMF, 70 °C, 
6 h. ii) 2, CuI, BtH, potassium tert-butoxide, 1,4-dioxane, 95 °C. *Reagents and conditions for 
4e: KOH, CS2, ethanol, 70 °C, overnight; 2M HCl, pH 5.  
†
4m and 4n were purchased from Chem-Impex International Inc. 
 
Analogs of 5k where the 1,3,4-oxadiazole ring was altered to 1,2,4 triazole (5p) and 1H-
imidazole (5q) were prepared according to the procedure outlined in Scheme 3. Compound 5p 
was synthesized by coupling of commercially purchased thiol 4o with intermediate 3-bromo 
benzo[b]thiophene 1,1-dioxide (2). Compound 5q was synthesized in a three-step reaction that 
involved the initial conversion of 2-bromo-1-(3-methoxyphenyl)ethan-1-one (6) to 2-amino-1-
(3-methoxyphenyl)ethan-1-one (7) using Delepine reaction conditions. In the second step, the 
corresponding thiol 4p was obtained by the treatment of compound 7 with potassium 
thiocyanate and glacial acetic acid at 140 °C for 2 h. Finally, the thiol 4p was coupled with the 
intermediate 3-bromo benzo[b]thiophene 1,1-dioxide (2) to give 5q. 
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Scheme 3. A) Synthetic route of compound 5p. Reagents and conditions: i) CuI, BtH, 
potassium tert-butoxide, 1,4-dioxane, 95 °C; B) synthetic route of compound 5q. Reagents and 
conditions: i) hexamine, DCM, rt, overnight; MeOH, HCl, 60 °C, 2h; ii) KSCN, glacial acetic 
acid, 140 °C, 2 h; iii) CuI, BtH, potassium tert-butoxide, 1,4-dioxane, 95 °C. 
 
2.2. Biological screening 
The designed compounds 5a-5o were initially tested for their inhibitory activity against 
Cryptococcus IMPDH in an enzymatic assay, with MPA as a positive control. MPA showed 
Cryptococcus IMPDH inhibitory activity with an IC50 of 0.12 ± 0.02 µM. All compounds, 
except compound 5l, exhibited high inhibitory activity on Cryptococcus IMPDH with IC50 
values of ≤1 µM (Table 1). The relatively similar IC50 values of all compounds against 
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Cryptococcus IMPDH suggested that any substitution made at the fifth position of the 1,3,4-
oxadiazole ring did not influence the level of Cryptococcus IMPDH inhibition. Given the level 
of similarity between Cryptococcus IMPDH and the human IMPDH isoforms, it was also 
important to assess the selectivity of the compounds. Therefore, all compounds were also tested 
for inhibitory activity against the human IMPDH isoforms I and II. Interestingly, compounds 
5f and 5l with 4-methyl carboxylate phenyl and 4-methoxy phenyl, respectively, at the fifth 
position of the 1,3,4-oxadiazole ring showed higher inhibitory selectivity (>30-fold) for 
Cryptococcus IMPDH (5f = 0.34 ± 0.07 µM, 5l = 1.7 ± 0.38 µM) over the human IMPDH I 
and II isoforms (5f and 5l = 30 µM).  
 
Since IMPDH is evolutionarily conserved, these compounds might also inhibit other 
pathogenic fungi such as C. albicans and A. fumigatus. As an initial effort we tested the 
synthesized compounds at cellular level against C. neoformans (type strain H99; ATCC 
208821) along with C. albicans (ATCC 90028), in order to evaluate their potential as broad-
spectrum antifungal agents. The in vitro antifungal screening was performed at a concentration 
range of 256 µg/mL to 0.12 µg/mL. We observed that compounds 5a-5d exhibited good 
inhibition against C. neoformans and C. albicans with MIC values ranging from 4 to 9 μM. 
Most of the other compounds showed prominent antifungal activity against C. neoformans but 
not C. albicans. These fungi have very different cellular structure for example C. neoformans 
has a polysaccharide capsule absent in C. albicans and this may alter the compound ability to 
penetrate the cell and subsequently inhibit IMPDH. 
 
Finally, the cytotoxicity of 5a-5o was tested using human embryonic kidney 293 (HEK293) 
and human liver hepatocellular carcinoma (HepG2) cell lines, with Tamoxifen as the positive 
control. All of these compounds displayed potent cytotoxic activity against the tested cell lines, 
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with CC50 values in the range of 2-6 µM for the HEK293 cell line and 14-31 µM for HepG2 
cell line (Table 1). Our attempts to reduce the cytotoxicity by the modification of the 1,3,4-
oxadiazole ring to 1,2,4 triazole in compound 5p and 1H-imidazole in compound 5q decreased 
Cryptococcus IMPDH inhibitory activity (5p: 14.6 ± 1.4 µM; 5q: 24.3 ± 3 µM) and antifungal 
activity (5p and 5q >172 µM) against both C. neoformans and C. albicans. This suggested that 
the 1,3,4-oxadiazole moiety was important for Cryptococcus IMPDH inhibitory activity but 
also lead to cytotoxicity. As IMPDH functions biologically as a homotetramer, with each 
monomer consisting of the active site for binding the substrate IMP and the cofactor NAD, the 
two most probable ways to inhibit IMPDH would be through binding to the active site or at 
subunit homotetrameric interfaces. 
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Table 1: Biological activities of 3-((5-substituted)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide derivatives. 
 
 
Compound 
 
R 
IMPDH inhibition (IC50)
a (µM) Antifungal activity (MIC)b 
(µM) 
Cytotoxicity 
(CC50)
c (µM) 
Cryptococcus 
IMPDH 
Human 
IMPDH I 
Human 
IMPDH II 
 
C. neoformans 
 
C. albicans 
 
HEK293 
 
HepG2 
MPA - 0.12 ± 0.02 0.26 ± 0.01 0.11 ± 0.01 - - - - 
Amphotericin B - - - - 0.25 0.18 - - 
Fluconazole - - - - 0.3 8 - - 
Tamoxifen - - - - - - 39.4 24.7 
 
5a  
 
1.06 ± 0.03 
 
13.2 ± 0.6 
 
4.2 ± 0.6 
 
6 
 
4 
 
5 
 
24 
 
5b 
 
 
0.59 ± 0.14 
 
6.3 ± 1 
 
2.6 ± 0.4 
 
4 
 
4 
 
4 
 
14 
  
12 
 
 
5c  
 
0.76 ± 0.07 
 
8.6 ± 1 
 
2.1 ± 0.2 
 
9 
 
6 
 
4 
 
17 
 
5d  
 
0.37 ± 0.06 
 
5.6 ± 1 
 
2.1 ± 0.1 
 
6 
 
6 
 
3 
 
20 
 
5e  
 
0.67 ± 0.16 
 
7.6 ± 0.2 
 
2.2 ± 0.7 
 
7 
 
46 
 
3 
 
15 
 
5f 
 
 
0.34 ± 0.07 
 
>30 
 
>30 
 
60 
 
>160 
 
4 
 
18 
 
5g  
 
0.23 ± 0.05 
 
7.2 ± 1 
 
1.2 ± 0.5 
 
6 
 
167 
 
4 
 
25 
 
5h 
 
 
 
0.40 ± 0.19 
 
 
10.1 ± 3.4 
 
 
1.6 ± 0.7 
 
 
6 
 
 
167 
 
 
6 
 
 
27 
 
5i 
 
 
0.49 ± 0.23 
 
11.1 ± 3.6 
 
1.5 ± 0.5 
 
16 
 
167 
 
3 
 
22 
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5j 
 
 
0.48 ± 0.10 
 
9.9 ± 0.6 
 
3.2 ± 1 
 
64 
 
172 
 
3 
 
16 
 
5k 
 
 
0.15 ± 0.05 
 
4.3 ± 0.4 
 
1.2 ± 0.2 
 
8 
 
172 
 
3 
 
20 
 
5l 
 
 
1.7 ± 0.38 
 
>30 
 
>30 
 
172 
 
172 
 
2 
 
22 
 
5m  
 
0.41 ± 0.06 
 
20.3 ± 1.4 
 
5.7 ± 0.6 
 
22 
 
90 
 
3 
 
31 
 
5n 
 
 
1.01 ± 0.14 
 
13.8 ± 0.6 
 
4.5 ± 0.1 
 
33 
 
>179 
 
4 
 
24 
 
5o 
 
 
0.16 ± 0.05 
 
20.4 ± 1.6 
 
4.4 ± 0.6 
 
>160 
 
>160 
 
4 
 
31 
aIC50 values of the compounds against Cryptococcus IMPDH and human IMPDH isoforms I and II. The values represent the average of at least 
three independent experiments and include standard deviations. 
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bAntifungal assays were carried out in duplicate with DMSO as the negative control, whereas amphotericin B and fluconazole were used as 
positive controls. 
cCytotoxic activities of the compounds with DMSO as the negative control and tamoxifen as the positive control
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2.3. Enzyme inhibition kinetics 
To further understand the mechanism of enzyme inhibition, a Michaelis-Menten enzyme 
kinetic analysis was performed. Initial experiments to determine the Michaelis constant (Km) 
were undertaken using the assay conditions [buffer containing 50 mM Tris-HCl (pH 8.0), 100 
mM KCl, 3 mM EDTA, 1 mM DTT] reported by Morrow et al. for their kinetic studies.12 
Similar to all other IMPDHs, Cryptococcus IMPDH also exhibited substrate inhibition at 
higher concentrations of NAD.11,12,21-24 Therefore, the Km value of NAD (Km(NAD) = 402 ± 91 
µM) was calculated by fitting kinetic data to a modified Michaelis-Menten equation that takes 
substrate inhibition into account (Equation 5). The apparent Km value of IMP (Km(IMP) = 94 ± 
18 µM) was determined with sub-saturating concentrations of NAD (700 µM) due to substrate 
inhibition and fitted into the classical Michaelis-Menten equation (Equation 4). The inhibition 
kinetics were also performed with MPA and compounds 5d and 5j by varying the concentration 
of one substrate, while the other substrate was maintained at a fixed concentration (Table 2). 
Consistent with previous reports, MPA showed uncompetitive inhibition (both Vmax and Km 
decreased) against both substrates, because it binds at the NAD site of the enzyme-substrate 
covalent complex (E-XMP*) formed after NADH leaves in the first step of the enzymatic 
reaction.11 
Initially, there was no inhibitory activity observed for compounds 5d and 5j when tested in the 
DTT-containing buffer, which was used to determine the Km values for the substrates. To 
investigate this, liquid chromatography-mass spectrometry (LC-MS) analysis of samples with 
compounds 5a-5o dissolved in a DTT-containing buffer was employed and showed their 
breakdown due to the attack of the free thiol group of DTT at the C3-position of the 
benzo[b]thiophene 1,1-dioxide moiety; 5-substituted-1,3,4-oxadiazole thiols were detected in 
the mass spectra (Figure 2). 
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Figure 2. A) LC-MS of compound 5d in buffer containing DTT. B) Mechanism of breakdown 
of compound 5d by the attack of a free thiol of DTT at the C3-position of benzo[b]thiophene 
1,1-dioxide. 
The degradation of the benzo[b]thiophene 1,1-dioxide moiety supported the recent findings of 
Dahlin et al.,13 who reported that the compounds with this chemotype as PAINS that formed 
covalent adducts when treated with glutathione (GSH); these adducts were detected using mass 
spectrometry (MS). Thus, inhibition kinetics for compounds 5d and 5j were performed using 
a buffer without DTT, and with different concentrations of one substrate and fixed 
concentrations of the other, with inhibitor concentrations from 0 to 20 µM. The plots obtained 
with the best fit of kinetic data from both compounds showed a decrease in the Vmax value and 
increase in the Km value (Figure 3 and Table 2). However, based on our studies (with DTT) 
and the observed thiol reactivity of these compounds,13 it could be possible that free thiol 
groups of cysteine residues of other proteins, including Cryptococcus IMPDH, could be 
modified. Cryptococcus IMPDH has a cysteine residue in the active site that makes a covalent 
interaction with IMP during initial step of biological catalysis, as well as other free cysteines. 
To confirm that the inhibitory activity shown by synthesized compounds was due to the 
modification of cysteine residues in IMPDH we performed MS studies. 
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Figure 3. Inhibition kinetics at different concentrations of compound 5d in conditions: A) by 
varying the concentration of NAD, while holding IMP at a fixed concentration (500 µM) B) 
by varying the concentration of IMP, while holding NAD at a fixed concentration (700 µM). 
The data were fitted to Equation 4 shown in experimental section.
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Table 2: Kinetic parameters for Cryptococcus IMPDH reaction and inhibition by compounds 5d and 5j. The concentrations of fixed substrate 
are 500 µM for IMP and 700 µM for NAD, with NAD concentration varied from 31.25 µM to 1300 µM and IMP from 25 µM to 800 µM. The 
data were fitted to Equation 4 shown in experimental section. 
 
Substrate  
Kinetic 
parameters 
Inhibition kinetics 
Fixed Varied No 
inhibitor 
MPA (µM) 5d (µM) 5j (µM) 
0.039 0.078 0.156 0.3 2.5 10 0.3 2.5 10 
 
IMP 
 
NAD 
Vmax 
(µM/min) 
1.5 1.1 0.6 0.26 1.5 1.3 1 1.5 1.5 1 
Km (µM) 257.5 ± 
23 
200 ± 
15 
137 ± 
12 
37 307 ± 22 336 ± 
17 
386 ± 23 278 ± 21.5 358.5 ± 36 355 
± 20 
Kcat (s
-1
) 1.5 1.1 0.6 0.25 1.5 1.3 1 1.5 1.5 1 
 
NAD 
 
IMP 
Vmax 
(µM/min) 
1.45 0.9 0.6 0.3 1.1 0.9 0.6 1.4 1 0.7 
Km (µM) 90 ± 12 64 ± 13 53 ± 
10 
32 ± 7.5 92.5 ± 19 187 ± 
44 
315.5 ± 95 93 ± 11 165 ± 26 258 
± 47 
Kcat (s
-1
) 1.38 0.9 0.6 0.3 1.1 0.9 0.6 1.4 1 0.7 
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2.4. Mass spectrometry studies 
Intact MS studies were conducted for samples of His-tagged Cryptococcus IMPDH in the 
absence and presence of compound 5d. Deconvoluted MS data showed that the intact mass of 
His-tagged Cryptococcus IMPDH as 59308 Da (theoretical mass = 59289 Da), and His-tagged 
Cryptococcus IMPDH incubated with compound 5d were determined as 59471 Da, 59633 Da 
and 59794 Da, which corresponded to single, double and triple modifications of cysteine 
residues from the addition of 164 Da (from attack of a thiol group in cysteine at the C3-position 
of benzo[b]thiophene 1,1-dioxide of 5d) (Figure 4). To investigate and characterize the 
modification of cysteine residues and confirm sites of cysteine modification in the sequence of 
Cryptococcus IMPDH, our mass spectrometry studies were extended to peptide sequencing. 
 
Figure 4. A) Mass spectrometry of His-tagged Cryptococcus IMPDH incubated with 
compound 5d. B) The deconvoluted mass spectrum showing intact masses of unmodified 
(59308.71 Da) and modified protein (59471.85 Da, 59634 Da and 59794.23 Da). 
The PeptideMass tool on the Expasy server25,26 predicted 35 tryptic peptide fragments 
generated from IMPDH, with the seven cysteines in seven unique peptides (Table S1). The 
catalytic cysteine (Cys 357) is present in fragment 5 (residue 349-382, M = 3455.7046 Da), 
which corresponded to the active site loop in Cryptococcus IMPDH. The fragments identified 
from the His-tagged Cryptococcus IMPDH sample showed good coverage of 97% with 95% 
confidence. The peptide fragment 5 produced an ion at m/z 1153.9 [(M + 3H)3+], which agreed 
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with the theoretical m/z value for 3+ protonated peptide (Figure S1). All cysteine containing 
peptide fragments were also detected by the database search (Figure S3-S7). 
 
Tryptic digestion of His-tagged Cryptococcus IMPDH incubated with compound 5d on ice 
and room temperature resulted in 81% coverage (at a 95% confidence) of the protein sequence 
and modification of 5 cysteines with the 164 Da from benzo[b]thiophene 1,1-dioxide from 
compound 5d (Figure S2 and S8-S11). This was consistent with the multiple modifications 
observed in the mass spectra of the undigested His-tagged Cryptococcus IMPDH incubated 
with compound 5d. Interestingly, the catalytic cysteine (Cys 357) containing peptide fragment 
5 (residues 349-382) was not detected in this sample, neither in the unmodified or modified 
form. Some differences with the enzyme-only digest were also detected, where peptide 
fragment 1 (residue 108-135) was found as a mis-cleaved form containing residues 125-135, 
with cyano group modification on cysteine.  
3. Conclusions 
3-((5-Substituted)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxides identified by 
high-throughput screening of Cryptococcus IMPDH were investigated as potential antifungals. 
All analogs 5a-5o had similar Cryptococcus IMPDH in vitro activities (≤ 1 µM) but exhibited 
potent human cell line cytotoxicities. Modifications to the 1,3,4-oxadiazole ring led to 
decreased cytotoxicity but also impaired Cryptococcus IMPDH inhibition and antifungal 
activities. The inhibition kinetics of compounds 5d and 5j using previously reported conditions 
that incorporated DTT did not show Cryptococcus IMPDH inhibitory activity due to the adduct 
formation of the benzo[b]thiophene 1,1-dioxide with DTT. Further investigation through MS 
studies confirmed that these compounds made covalent bound to multiple cysteine residues in 
Cryptococcus IMPDH in a promiscuous fashion. This reinforces the importance of eliminating 
PAINS from screening libraries. 
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4. Experimental section 
4.1. Chemistry 
4.1.1. General Methods and Materials 
All starting materials were purchased from standard commercial sources and used without 
further purification, unless otherwise stated. All reactions were carried out with magnetic 
stirring using magnetic bars under an inert nitrogen atmosphere with anhydrous solvents unless 
otherwise stated. The progress of reactions was monitored by either thin-layer chromatography 
(TLC) on 0.25 mm silica gel plates (TLC) on 0.25 mm silica gel plates (60F-254) and visualized 
with UV light or a KMnO4 dip. Analytical 
1H and 13C NMR spectra were recorded in deuterated 
solvents at 298 K on a Varian Unity 400 MHz or Bruker Advance 600 MHz spectrometers. 
The chemical shifts are reported as a part per million (ppm) downfield from tetramethylsilane 
(TMS) and coupling constants (J) were calculated in hertz (Hz). All final compounds were 
purified to ≥95% by the Grace Reveleris chromatography instrument using UV detection. High 
resolution mass spectrometry (HRMS) was performed on the Bruker MicroTOF mass 
spectrometer. 
4.1.2. General procedure for synthesis of 5-substituted 1,3,4-oxadiazole-2-thiols 
To a solution of acid hydrazide in anhydrous 5-15 mL of DMF, carbon disulfide (2.5 mL/mmol) 
was added at room temperature and under a nitrogen atmosphere. The reaction mixture was 
then heated to 40 °C for 15 minutes and then to 70 °C for 4-8 h until the reaction was completed. 
After completion, the reaction mixture was cooled to room temperature and poured dropwise 
into ice cold water. The solids formed were separated by filtration, washed with water and dried 
in vacuo. 
5-(Pyridin-2-yl)-1,3,4-oxadiazole-2-thiol (4a) Prepared from pyridine-2-carbohydrazide 3a 
(0.3 g, 21.8 mmol) and CS2 (0.5 g, 6.50 mmol) according to general procedure A. Yield 170 
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mg (43%); yellow solid; MS (ESI) m/z (%): 180.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 
14.8 (s, 1H), 8.76 (dd, J = 1.7, 1.1 Hz, 1H), 8.09-7.97 (m, 2H), 7.64 (dd, J = 4.8, 1.9 Hz, 1H). 
5-(Pyridin-3-yl)-1,3,4-oxadiazole-2-thiol (4b) Prepared from pyridine-3-carbohydrazide 3b 
(0.3 g, 21.8 mmol) and CS2 (0.5 g, 6.50 mmol) according to general procedure A. Yield 120 
mg (30%); yellow solid; MS (ESI) m/z (%): 180.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 
9.04 (dd, J = 2.3, 0.9 Hz, 1H), 8.79 (dd, J = 4.9, 1.6 Hz, 1H), 8.31-8.20 (m, 1H), 7.68-7.54 (m, 
1H). 
5-(Pyridin-4-yl)-1,3,4-oxadiazole-2-thiol (4c) Prepared from pyridine-4-carbohydrazide 3c 
(0.3 g, 21.8 mmol) and CS2 (0.5 g, 6.50 mmol) according to general procedure A. Yield 180 
mg (50%); yellow solid; MS (ESI) m/z (%): 180.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 
9.05-8.92 (m, 2H), 8.09 - 7.97 (m, 2H). 
5-(Phenyl)-1,3,4-oxadiazole-2-thiol (4d) Prepared from benzohydrazide 3d (1.0 g, 5.6 mmol) 
and CS2 (1.6 g, 21.0 mmol) according to general procedure A. Yield 0.52 g (40%); yellow 
solid; MS (ESI) m/z (%): 179.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 14.7 (s, 1H), 7.93-
7.85 (m, 2H), 7.69-7.55 (m, 2H). 
Methyl 4-(5-mercapto-1,3,4-oxadiazol-2-yl)benzoate (4f) Prepared from methyl 4-
(hydrazinecarbonyl)benzoate 3f (0.15 g, 0.77 mmol) and CS2 (0.12 g, 1.50 mmol) according to 
general procedure A. Yield 120 mg (66%); yellow solid; MS (ESI) m/z (%): 237.2 [M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.15- 8.09 (m, 2H), 8.06-8.00 (m, 2H), 3.90 (d, J 
= 1.4 Hz, 3H). 
5-(2-Chlorophenyl)-1,3,4-oxadiazole-2-thiol (4g) Prepared from 2-chlorobenzohydrazide 3g 
(2.0 g, 11.7 mmol) and CS2 (2.6 g, 34.2 mmol) according to general procedure A. Yield 1.53 g 
(63%); yellow solid; MS (ESI) m/z (%): 213.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.88 
(ddd, J = 7.8, 1.7, 0.5 Hz, 1H), 7.67 (dd, J = 1.4, 0.5 Hz, 1H), 7.61 (dd, J = 1.4, 0.5 Hz, 1H), 
7.52 (dd, J = 1.4, 0.5 Hz, 1H). 
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5-(3-Chlorophenyl)-1,3,4-oxadiazole-2-thiol (4h) Prepared from 3-chlorobenzohydrazide 3h 
(2.0 g, 11.7 mmol) and CS2 (2.6 g, 34.2 mmol) according to general procedure A. Yield 1.4 g 
(58%); yellow solid; MS (ESI) m/z (%): 213.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 
14.79 (s, 1H), 7.84-7.80 (m, 1H), 7.80 (dd, J = 1.6, 1.1 Hz, 1H), 7.67 (dd, J = 2.1, 1.1 Hz, 1H), 
7.58 (dd, J = 1.6, 0.6 Hz, 1H). 
5-(4-Chlorophenyl)-1,3,4-oxadiazole-2-thiol (4i) Prepared from 4-chlorobenzohydrazide 3i 
(2.0 g, 11.7 mmol) and CS2 (2.6 g, 34.2 mmol) according to general procedure A. Yield 1.4 g 
(58%); yellow solid; MS (ESI) m/z (%): 213.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.94-
7.81 (m, 2H), 7.67 - 7.58 (m, 2H). 
5-(2-Methoxyphenyl)-1,3,4-oxadiazole-2-thiol (4j) Prepared from 2-
methoxybenzohydrazide 3j (2.0 g, 12.0 mmol) and CS2 (2.74 g, 36.0 mmol) according to 
general procedure A. Yield 1.7 g (68%); yellow solid; MS (ESI) m/z (%): 209.2 [M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 7.70 (dd, J = 7.7, 1.8 Hz, 1H), 7.62-7.48 (m, 1H), 7.22 (dd, J = 
8.5, 0.9 Hz, 1H), 7.08 (td, J = 7.5, 0.9 Hz, 1H), 3.86 (s, 3H). 
5-(3-Methoxyphenyl)-1,3,4-oxadiazole-2-thiol (4k) Prepared from 3-
methoxybenzohydrazide 3k (2.0 g, 12.0 mmol) and CS2 (2.74 g, 36.0 mmol) according to 
general procedure A. Yield 1.6 g (64%); yellow solid; MS (ESI) m/z (%): 209.2 [M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 7.50-7.41 (m, 2H), 7.31 (dd, J = 1.5, 0.4 Hz, 1H), 7.17 (dd, J = 
2.7, 1.3 Hz, 1H), 3.81 (s, 3H). 
5-(4-Methoxyphenyl)-1,3,4-oxadiazole-2-thiol (4l) Prepared from 4-
methoxybenzohydrazide 3l (2.0 g, 12.0 mmol) and CS2 (2.74 g, 36.0 mmol) according to 
general procedure A. Yield 1.5 g (60%); yellow solid; MS (ESI) m/z (%): 209.2 [M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 7.83-7.74 (m, 2H), 7.17-7.05 (m, 2H), 3.81 (s, 3H).  
Synthesis of 5-(Cyclohexyl)-1,3,4-oxadiazole-2-thiol (4e) To solution of synthesized 
cyclohexyl hydrazide 3e (0.5 g, 3.52 mmol) in ethanol, potassium hydroxide (0.25 g, 4.46 
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mmol) and carbon disulfide (1.3 g, 17.1mmol) were added at room temperature and under a 
nitrogen atmosphere. The reaction mixture was then heated to 70 °C overnight. The reaction 
mixture was evaporated in vacuo and acidified to pH 5 with 2 M HCl. The aqueous layer was 
extracted with ethyl acetate (3 × 50 mL) and organics were dried (MgSO4) and concentrated in 
vacuo to yield 5-(cyclohexyl)-1,3,4- oxadiazole-2-thiol (4e) as colorless oil; yield 0.25 mg 
(39%) MS (ESI) m/z (%): 185.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 2.77 (tt, J = 10.9, 
3.7 Hz, 1H), 1.94-1.87 (m, 2H), 1.71-1.55 (m, 3H), 1.45-1.16 (m, 5H). 
4.1.3. Synthesis of 5-(3-Methoxyphenyl)-1H-imidazole-2-thiol (4p)  
Step A. To a solution of 2-bromo-1-(3-methoxyphenyl)ethan-1-one) (2.0 g, 8.70 mmol) in 20 
mL of dichloromethane, hexamine (1.46 g, 10.4 mmol) was added and the mixture was stirred 
at room temperature overnight. The white solids formed were separated by filtration and dried 
in vacuo. Then solids were dissolved in 15 mL of methanol and 2 mL of c. HCl and heated at 
60 °C for 3 h. The reaction completion was monitored by LC-MS and then reaction mixture 
was cooled and filtered to separate the inorganics. Excess solvent from the filtrate was 
evaporated in vacuo and solids were neutralized with aqueous solution of sat. NaHCO3, 
separated by filtration and dried in vacuo to give 2-amino-1-(3-methoxyphenyl)ethan-1-one as 
a dark brown solid. Yield: 0.8 g, 57%; MS (ESI) m/z (%): 166.2 [M+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ 7.58 (dt, J = 7.8, 1.2 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.27 (dd, J = 2.6, 0.9 Hz, 1H), 
4.55 (s, 2H), 3.81 (s, 3H). 
Step B. To a solution of 2-amino-1-(3-methoxyphenyl)ethan-1-one (0.2 g, 1.21 mmol) in 4 mL 
of glacial acetic acid, potassium thiocyanate (0.15g, 1.57 mmol) was added at room 
temperature and heated to 140 °C for 2 h. The reaction mixture was then diluted with water (25 
mL) and extracted with ethyl acetate 2 × 50 mL. The organics were dried (MgSO4) and 
evaporated in vacuo to give 5-(3-methoxyphenyl)-4H-1,2,4-triazole-3-thiol (4p) as a dark 
brown solid. Yield: 70 mg, 29%; MS (ESI) m/z (%): 207.2 [M+H]+. 1H NMR (400 MHz, 
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DMSO-d6) δ 12.47 (s, 1H), 12.09 (s, 1H), 7.38 (t, J = 2.3 Hz, 1H), 7.28 - 7.18 (m, 3H), 6.78 
(dd, J = 2.5, 1.6 Hz, 1H), 3.74 (s, 3H). 
4.1.4. Synthesis of 3-bromobenzo[b]thiophene 1,1-dioxide (2)  
To solution of 1 (1.0 g, 4.70 mmol) in dichloromethane, mCPBA (4.4 g, 25.0 mmol) was added 
at 0 °C and the mixture was warmed to room temperature and left stirring for 24 h. TLC was 
spotted with a small aliquot of the reaction mixture, which indicated that the reaction was 
completed. Excess DCM was added and washed with sat. NaHCO3 (aq) (50 mL × 2), followed 
by brine solution (50 mL × 1). The organics were dried (MgSO4) and evaporated in vacuo. The 
residue was then recrystallized from absolute ethanol to get product in good yield. White 
crystalline solid; Yield: 0.65 mg, 57%; MS (ESI) m/z (%): 247 [M+H]+; 1H NMR (400 MHz, 
CDCl3) δ 7.76-7.53 (m, 4H), 6.98 (s, 1H). 
4.1.5. General procedure for coupling of 3-bromobenzo[b]thiophene 1,1-dioxide with 5-
substituted 1,3,4-oxadiazole-2-thiols 
To a solution of 3-bromobenzo[b]thiophene 1,1-dioxide 2 dissolved in 1,4-dioxane (5 
mL/mmol), CuI (0.5 mol %) and benzotriazole (1.0 mol %) were added and the mixture was 
stirred for 10 min at room temperature. Then thiols 4a-4p and potassium tert-butoxide (1.5 eq) 
were added to the reaction mixture, which was stirred at 95 °C overnight. The reaction 
completion was monitored by LC-MS analysis. Then reaction mixture was cooled to room 
temperature and excess solvent was evaporated in vacuo. The residue obtained was dissolved 
in DMSO/acetonitrile (3:1) and loaded onto C18 column (GRACE Flash) for purification using 
water/acetonitrile as the mobile phase. The fractions that contained product were collected and 
lyophilized to provide 4a-4q in good yields. 
3-((5-(Pyridin-2-yl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5a) Prepared 
from thiol 4a (50.0 mg, 0.28 mmol) and 2 (82 mg, 0.33 mmol) according to general procedure 
E. Yield 16 mg (17%); light yellow solid; MS (ESI) m/z (%): 344.1 [M+H]+. 1H NMR (600 
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MHz, DMSO-d6) δ 8.82 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.25 (dt, J = 7.9, 1.1 Hz, 1H), 8.10 (td, 
J = 7.8, 1.8 Hz, 1H), 8.02-7.99 (m, 1H), 7.84-7.80 (m, 1H), 7.79-7.75 (m, 2H), 7.73 (s, 1H), 
7.69 (dd, J = 4.8, 1.2 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ 167.1, 157.6, 150.8, 142.9, 
138.7, 138.4, 136.8, 135.0 ,132.5, 129.4, 127.3, 127.0, 123.8, 123.3, 121.8; HRMS calculated 
for C15H10N3O3S2: 344.0158, found 344.0153.  
3-((5-(Pyridin-3-yl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5b) Prepared 
from thiol 4b (50.0 mg, 0.28 mmol) and 2 (82 mg, 0.33 mmol) according to general procedure 
E. Yield 14 mg (15%); light yellow solid; MS (ESI) m/z (%): 344.1 [M+H]+. 1H NMR (600 
MHz, DMSO-d6) δ 9.22 (d, J = 2.1 Hz, 1H), 8.86 (dd, J = 5.0, 1.6 Hz, 1H), 8.43 (dt, J = 8.0, 
2.0 Hz, 1H), 8.00 (d, J = 7.4 Hz, 1H), 7.85-7.74 (m, 4H), 7.69 (dd, J = 8.0, 5.0 Hz, 1H). 13C 
NMR (150 MHz, DMSO-d6) δ 166.2, 157.3, 153.4, 147.9, 138.7, 136.8, 135.0, 134.9, 132.5, 
129.4, 126.9, 124.8, 123.3, 121.8, 120.2; HRMS calculated for C15H10N3O3S2: 344.0158, found 
344.0164. 
3-((5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5c) Prepared 
from thiol 4c (50.0 mg, 0.28 mmol) and 2 (82 mg, 0.33 mmol) according to general procedure 
E. Yield 12 mg (13%); light yellow solid; MS (ESI) m/z (%): 344.1 [M+H]+. 1H NMR (600 
MHz, DMSO-d6) δ 8.89 - 8.86 (m, 2H), 8.01 (t, J = 0.9 Hz, 1H), 7.99-7.98 (m, 2H), 7.84-7.75 
(m, 4H). 13C NMR (150 MHz, DMSO-d6) δ 166.3, 158.0, 151.4, 138.51, 136.8, 134.9, 132.5, 
130.6, 129.4, 127.1, 123.4, 121.8, 120.8; HRMS calculated for C15H10N3O3S2: 344.0158, found 
344.0168. 
3-((5-Phenyl-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5d) Prepared from 
thiol 4d (50.0 mg, 0.28 mmol) and 2 (82 mg, 0.33 mmol) according to general procedure E. 
Yield 35 mg (37%); light yellow solid; MS (ESI) m/z (%): 343.2 [M+H]+. 1H NMR (600 MHz, 
DMSO-d6) δ 8.06-8.04 (m, 2H), 8.00-7.96 (m, 1H) 7.83-7.80 (m, 1H), 7.78-7.74 (m, 3H), 7.70-
7.67 (m, 1H), 7.65-7.62 (m, 2H). 13C NMR (150 MHz, DMSO-d6) δ 167.9, 156.6, 138.8, 136.8, 
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134.9, 133.0, 132.5, 129.9, 129.9, 129.4, 126.8, 123.5, 23.3, 121.8; HRMS calculated for 
C16H11N2O3S2: 343.0205, found 343.0211. 
3-((5-Cyclohexyl-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5e) Prepared 
from thiol 4e (50.0 mg, 0.27 mmol) and 2 (79 mg, 0.32 mmol) according to general procedure 
E. Yield 18 mg (16%); light yellow solid; MS (ESI) m/z (%): 349.5 [M+H]+. 1H NMR (600 
MHz, DMSO-d6) δ 7.98 (dd, J = 7.5, 4.6 Hz, 1H), 7.82 - 7.74 (m, 2H), 7.70 (dd, J = 7.6, 4.6 
Hz, 1H), 7.60 (d, J = 4.9 Hz, 1H), 3.04 (td, J = 11.1, 5.0 Hz, 1H), 2.06 - 2.01 (m, 2H), 1.74 
(dt, J = 13.3, 4.3 Hz, 2H), 1.67-1.60 (m, 1H), 1.55 (q, J = 11.9 Hz, 2H), 1.43 - 1.34 (m, 2H), 
1.27 (td, J = 12.2, 4.1 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ 174.0, 156.4, 138.9, 137.1, 
135.2, 132.8, 129.7, 127.1, 123.5, 122.1, 35.1, 30.00, 25.88, 25.3; HRMS calculated for 
C16H17N2O3S2: 349.0675, found 349.0686. 
Methyl 4-(5-((1,1-dioxidobenzo[b]thiophen-3-yl)thio)-1,3,4-oxadiazol-2-yl)benzoate (5f) 
Prepared from thiol 4f (50.0 mg, 0.21 mmol) and 2 (61.0 mg, 0.25 mmol) according to general 
procedure E. Yield 5 mg (6%); light yellow solid; MS (ESI) m/z (%): 401.4 [M+H]+. 1H NMR 
(600 MHz, DMSO-d6) δ 8.24-8.16 (m, 4H), 8.00 (dt, J = 7.5, 1.0 Hz, 1H), 7.87- 7.73 (m, 4H), 
3.91 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 167.2, 165.8, 157.3, 138.7, 136.8, 134.9, 133.1, 
132.5, 130.6, 129.4, 127.8, 127.4, 126.9, 123.3, 121.8, 53.0; HRMS calculated for 
C18H13N2O5S2: 401.0260, found 401.0260. 
3-((5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5g) 
Prepared from thiol 4g (50.0 mg, 0.23 mmol) and 2 (67 mg, 0.27 mmol) according to general 
procedure E. Yield 24 mg (32%); dark brown solid; MS (ESI) m/z (%): 377.2 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 8.07 (dd, J = 7.9, 1.7 Hz, 1H), 8.01 - 7.99 (m, 1H), 7.84 - 7.80 
(m, 2H), 7.78 - 7.73 (m, 3H), 7.69 (dd, J = 7.4, 1.7 Hz, 1H), 7.62 - 7.59 (m, 1H). 13C NMR 
(150 MHz, DMSO-d6) δ 165.8, 157.5, 138.0, 136.8, 134.9, 134.1, 132.5, 132.3, 131.9, 131.7, 
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129.5, 128.3, 127.9, 123.4, 122.3, 121.8; HRMS calculated for C16H10ClN2O3S2: 376.9816, 
found 376.9802 
3-((5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5h) 
Prepared from thiol 4h (50.0 mg, 0.23 mmol) and 2 (67 mg, 0.27 mmol) according to general 
procedure E. Yield 26 mg (33%); dark brown solid; MS (ESI) m/z (%): 377.2 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 8.06-7.99 (m, 3H), 7.84-7.81 (m, 1H), 7.79-7.75 (m, 4H), 7.68 
(t, J = 8.0 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ 166.8, 157.2, 138.6, 136.8, 134.9, 134.5, 
132.8, 132.5, 132.0, 129.4, 127.0, 126.8, 126.1, 125.4, 123.3, 121.8; HRMS calculated for 
C16H10ClN2O3S2: 376.9816, found 376.9812. 
3-((5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5i) 
Prepared from thiol 4i (50.0 mg, 0.23 mmol) and 2 (67.0 mg, 0.27 mmol) according to general 
procedure E. Yield 20 mg (26%); dark brown solid; MS (ESI) m/z (%): 377.2 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 8.09-8.03 (m, 2H), 7.99 (dd, J = 7.1, 1.6 Hz, 1H), 7.83-7.74 (m, 
4H), 7.73-7.70 (m, 2H). 13C NMR (150 MHz, DMSO-d6) δ 167.2, 156.9, 138.7, 137.7, 136.8, 
134.9, 132.5, 130.1, 129.4, 129.2, 126.8, 123.3,122.4, 121.8; HRMS calculated for 
C16H10ClN2O3S2: 376.9816, found 376.9801. 
3-((5-(2-Methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5j) 
Prepared from thiol 4j (50.0 mg, 0.24 mmol) and 2 (67.0 mg, 0.28 mmol) according to general 
procedure E. Yield 18 mg (18%); light yellow solid; MS (ESI) m/z (%): 373.1 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 8.00 (d, J = 7.4 Hz, 1H), 7.92 (dd, J = 7.9, 1.7 Hz, 1H), 7.81 (t, 
J = 7.5 Hz, 1H), 7.78-7.73 (m, 2H), 7.71 (s, 1H), 7.66-7.62 (m, 1H), 7.28 (d, J = 8.6 Hz, 1H), 
7.16 (t, J = 7.6 Hz, 1H), 3.88 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 166.6, 157.9, 156.5, 
138.3, 136.8, 134.9, 134.6, 132.5, 130.7, 127.4, 123.3, 123.3, 121.8, 121.2, 113.2, 112.0, 56.4; 
HRMS calculated for C17H13N2O4S2: 373.0311, found 373.0309. 
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3-((5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5k) 
Prepared from thiol 4k (50.0 mg, 0.24 mmol) and 2 (67.0 mg, 0.28 mmol) according to general 
procedure E. Yield 10 mg (10%); light yellow solid; MS (ESI) m/z (%): 373.1 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 7.99 (dd, J = 7.8, 1.2 Hz, 1H), 7.84-7.79 (m, 1H), 7.79-7.72 (m, 
3H), 7.62 (dt, J = 7.7, 1.2 Hz, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.51 (dd, J = 2.7, 1.6 Hz, 1H), 
7.26 (dd, J = 2.7, 1.0 Hz, 1H), 3.85 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 167.6, 160.1, 
156.8, 138.7, 136.8, 134.9, 132.5, 131.3, 129.4, 127.1, 124.6, 123.3, 121.8, 119.7, 119.0, 112.0, 
55.9; HRMS calculated for C17H13N2O4S2: 373.0294, found 373.0311. 
3-((5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5l) 
Prepared from thiol 4l (50.0 mg, 0.24 mmol) and 2 (67.0 mg, 0.28 mmol) according to general 
procedure E. Yield 15 mg (15%); light yellow solid; MS (ESI) m/z (%): 373.1 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 8.02-7.96 (m, 3H), 7.81 (td, J = 7.5, 1.2 Hz, 1H), 7.79-7.74 (m, 
2H), 7.72 (s, 1H), 7.20-7.15 (m, 2H), 3.86 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 167.8, 
162.9, 155.7, 138.9, 136.8, 134.9, 132.5, 129.4, 129.3, 126.6, 123.2, 121.8, 115.7, 115.3, 56.0; 
HRMS calculated for C17H13N2O4S2: 373.0311, found 373.0293. 
3-((5-(p-Tolyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5m) Prepared 
from thiol 4m (50.0 mg, 0.25 mmol) and 2 (73.0 mg, 0.3 mmol) according to general procedure 
E. Yield 13 mg (18%); light yellow solid; MS (ESI) m/z (%): 157.4 [M+H]+. 1H NMR (600 
MHz, DMSO-d6) δ 8.01-7.99 (m, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.84- 7.80 (m, 1H), 7.79-7.75 
(m, 2H), 7.74 (s, 1H), 7.45 (d, J = 8.0 Hz, 2H), 2.42 (s, 3H). 13C NMR (150 MHz, DMSO-d6) 
δ 168.0, 156.2, 143.3, 138.8, 136.8, 134.9, 132.5, 130.4, 129.4, 127.3, 126.8, 123.3, 121.8, 
120.7, 21.6; HRMS calculated for C17H13N2O3S2: 357.0362, found 357.0376. 
3-((5-(4-Aminophenyl)-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5n) 
Prepared from thiol 4n (50.0 mg, 0.25 mmol) and 2 (73.0 mg, 0.3 mmol) according to general 
procedure E. Yield 30 mg (26%); Dark yellow solid; MS (ESI) m/z (%): 358.2 [M+H]+. 1H 
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NMR (600 MHz, DMSO-d6) δ 7.98 (d, J = 7.4 Hz, 1H), 7.84 - 7.79 (m, 1H), 7.79 - 7.72 (m, 
2H), 7.71-7.65 (m, 3H), 6.72-6.66 (m, 2H), 6.08 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 
168.7, 154.1, 153.4, 139.2, 136.9, 134.9, 132.5, 129.4, 129.0, 126.3, 123.2, 121.81, 113.9, 
109.4; HRMS calculated for C16H12N3O3S2: 358.0315, found 358.0324. 
3-((5-(3-Methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)benzo[b]thiophene 1,1-dioxide (5p) 
Prepared from thiol 4o (50.0 mg, 0.24 mmol) and 2 (68.0 mg, 0.28 mmol) according to general 
procedure E. Yield 19 mg (19%); light yellow solid; MS (ESI) m/z (%): 372.4 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 7.95 (d, J = 7.5 Hz, 1H), 7.81 (t, J = 7.5 Hz, 1H), 7.74 (q, J = 
7.5 Hz, 2H), 7.67 - 7.57 (m, 2H), 7.48 (t, J = 7.8 Hz, 1H), 7.19 (s, 1H), 7.10 (d, J = 8.3 Hz, 
1H), 3.85 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 160.0, 137.2, 135.0, 134.6, 132.6, 132.2, 
131.0, 130.8, 130.0, 125.1, 122.8, 122.5, 121.4, 119.0, 116.7, 111.7, 55.8; HRMS calculated 
for C17H13N3O3S2: 372.0309, found 372.0309. 
3-((5-(3-Methoxyphenyl)-1H-imidazol-2-yl)thio)benzo[b]thiophene 1,1-dioxide (5q) 
Prepared from thiol 4p (50.0 mg, 0.24 mmol) and 2 (68.0 mg, 0.28 mmol) according to general 
procedure E. Yield 19 mg (19%); light yellow solid; MS (ESI) m/z (%): 371.4 [M+H]+. 1H 
NMR (600 MHz, DMSO-d6) δ 7.98 - 7.91 (m, 2H), 7.79 (td, J = 7.6, 1.2 Hz, 1H), 7.76 - 7.69 
(m, 2H), 7.39 (dd, J = 7.2, 5.2 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 6.76 
(s, 1H), 3.80 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 160.06, 145.2, 137.4, 134.6, 132.3, 
130.18, 129.8, 122.7, 121.7, 121.5, 117.2, 113.0, 110.0, 55.5; HRMS calculated for 
C18H14N2O3S2: 371.0518, found 371.0518. 
Synthesis of N-(4-(5-((1,1-Dioxidobenzo[b]thiophen-3-yl)thio)-1,3,4-oxadiazol-2- 
yl)phenyl)acetamide (5o) To solution of 5n (25.0 mg, 0.069 mmol) in 3 mL of anhydrous 
THF, triethylamine (7 mg, 0.070 mmol) was added at room temperature. The reaction mixture 
was stirred for 5 mins and cooled to 0 °C and acetyl chloride (54 mg, 0.070 mmol) was added 
dropwise. The reaction mixture was then warmed to room temperature and stirred for 1 h. The 
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reaction completion was monitored by LC-MS and excess THF was evaporated in vacuo. The 
residue obtained was dissolved in 3 mL of DMSO/Acetonitrile (3:1) and loaded onto a C18 
column (GRACE Flash) for purification using water/acetonitrile as a mobile phase. The pure 
fractions containing product were collected and lyophilized to get 5o. Yield 6 mg (22%); white 
solid; MS (ESI) m/z (%): 400.2 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 10.37 (s, 1H), 8.02-
7.96 (m, 3H), 7.86-7.80 (m, 3H), 7.79-7.75 (m, 2H), 7.72 (s, 1H), 2.10 (s, 3H). 13C NMR (150 
MHz, DMSO-d6) δ 169.4, 167.8, 155.8, 143.5, 139.0, 136.8, 134.9, 132.5, 129.4, 128.4, 126.6, 
123.3, 121.8, 119.4, 117.6, 24.6; HRMS calculated for C18H14N3O4S2: 400.0420, found 
400.0422. 
5. Expression and Purification of C. neoformans and human IMPDH: 
C. neoformans IMPDH was produced by recombinant expression in E. coli BL21 (DE3) pLysS 
and purified as described previously.27 Human IMPDH isoforms I and II were inserted into 
pMCSG7 using ligation independent cloning.28 The enzymes were expressed in E. coli BL21 
(DE3) pLysS in autoinduction media at 37 °C for approximately 8 h, with shaking at 220 rpm.29 
After expression, cells were harvested and the protein was purified as described previously,27 
except that the His-tag was cleaved using the tobacco etch virus protease (0.4 mg, at 4°C, 
overnight) and a reverse immobilized metal affinity chromatography step was included to 
remove His-tagged contaminants before size exclusion chromatography.  
 
6. IMPDH enzymatic assay 
Each assay contained 50 mM Tris-HCl, pH 8, 150 mM KCl, 2 mM EDTA, 2% DMSO, 
0.0025% Tween-20 and 0.005% BSA, 0.2 μM IMPDH, in addition to 500 µM IMP and NAD 
for Cryptococcus IMPDH and 100 µM NAD and 125 μM IMP for human IMPDH I and II. 
Reactions were performed in 96-well UV-star flat bottom plates (Greiner Bio-one, Austria) in 
a POLAR star Omega Plate Reader (BMG LABTECH, Germany) and initiated by addition of 
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IMP. The rate of NADH was followed at 340 nm (ε = 6.22 mM-1cm-1) production in the 
presence of each compound at a particular concentration was determined and the enzyme 
activity calculated by the equation below: 
𝑁𝐴𝐷𝐻 𝑚𝑀/ min =
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 (𝐴340/𝑚𝑖𝑛)
𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑁𝐴𝐷𝐻 (6.22 𝑚𝑀−1𝑐𝑚−1)
 ×  1 𝑐𝑚          (1) 
 
𝑈/𝑚𝑔 =
𝑁𝐴𝐷𝐻 𝑚𝑀/𝑚𝑖𝑛
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐼𝑀𝑃𝐷𝐻 (𝑚𝑔/𝑚𝑙)
                           (2) 
All synthesized compounds and the positive control MPA (all 1 mM stocks in DMSO) were 
tested 20 to 0.02 μM (for Cryptococcus IMPDH) and 30 to 0.93 μM (for hIMPDH I and II). 
Controls with no inhibitor and 20 μM MPA (resulting in complete inhibition of the enzyme) 
were used to calculate the percent activity and this was plotted against the log inhibitor 
concentration and fitted as the log(inhibitor) vs normalized response - variable slope equation 
(3) in Prism version 6 (GraphPad, San Diego, California) to determine the IC50. All plates were 
checked for uniform wells and had a Z'-factor >0.5.30 
             𝑦 =
100
(1+10(𝑥−log 𝐼𝐶50))
                                                    (3) 
Where y is the % activity of the enzyme and x is the log molar concentration of the 
compound. 
7. Enzyme inhibition kinetics: 
Kinetics studies of Cryptococcus IMPDH with substrates (IMP and NAD) and compound 5d 
and 5j were carried out in the same way as IC50 assays, by monitoring the absorbance at 340 
nM of NADH produced from the reaction. For Km determination, reactions were performed 
using the previously reported assay buffer [50 mM Tris-HCl (pH 8.0), 100 mM KCl, 3 mM 
EDTA, 1 mM DTT] with concentrations of IMP and NAD varying from 5000 µM to 39 µM 
and fixed second substrate concentrations of 500 µM for IMP and 700 µM for NAD. All 
reactions were initiated by the addition of the IMPDH enzyme, reaching a final concentration 
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of 100 nM in the total volume. The rate of reaction and enzyme activity for all reactions were 
calculated by using the extinction coefficient value of NADH (ε = 6.22 mM-1cm-1). The data 
was fitted to the Michaelis-Menten equation (Equation 4) by non-linear regression analysis 
using GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla California USA 
(www.graphpad.com).  
𝑣 =  
𝑉𝑚𝑎𝑥[𝑋]
𝐾𝑚 +  [𝑋]
          (4) 
Where substrate inhibition was observed ([NAD]>1300 µM), the data was fitted to a 
modified Michaelis-Menten equation (Equation 5) 
𝑣 =
𝑉𝑚𝑎𝑥[𝑋]
𝐾𝑚 +  [𝑋] (1 +
[𝑋]
𝐾𝑖
)
          (5) 
where 𝑣 is the initial velocity; 𝑉𝑚𝑎𝑥  is the maximum enzyme velocity; 𝐾𝑚 is the Michaelis-
Menten constant; [𝑋] is substrate concentration; and 𝐾𝑖 is the dissociation constant for substrate 
binding accounting for two-substrate binding to the enzyme. 
Inhibition kinetics analyses were performed in an assay buffer without DTT [50 mM Tris-
HCl (pH (8.0), 100 mM KCl, 3 mM EDTA], because compounds 5a-5o showed degradation 
in the presence of DTT. MPA is an inhibitor of IMPDH from all species and was tested at four 
different concentrations (312 nM, 156 nM, 78 nM, 39 nM) in reactions with concentration of 
IMP varying from 25 µM to 800 µM in the presence of 700 µM NAD in one set of reactions, 
and with NAD varying from 31.25 µM to 1300 µM in the presence of 500 µM IMP in another 
set of reactions. Compounds 5d and 5j were also tested under the same settings as MPA but at 
eight different concentrations (20 µM, 10 µM, 5 µM, 2.5 µM, 1.25, 0.62 µM and 0.31 µM) to 
determine the type of inhibition. All inhibition assays were performed in 96-well plates 
(Greiner Bio-one, Austria) using a Spectramax 190 microplate reader (Molecular devices, 
Sunnyvale, CA 94089 USA). The enzyme activity data was as described above, and the type 
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of inhibition was evaluated by determining the changes in Km and Vmax values in the absence 
and the presence of the inhibitors. 
8. Antifungal assay 
Based on a standard MIC assay, all the synthesized test compounds along with standard 
antifungals (amphotericin B and fluconazole) were serially diluted two-fold across the wells of 
96-well NBS plates to determine their antifungal activity. The concentrations of standard 
antifungals ranged from 256 μg/mL to 0.12 μg/mL and of the test compounds from 512 μg/mL 
to 0.24 μg/mL, with final volumes of 50μL per well, plated in duplicate. Then, 50 μL of a fungi 
suspension that was previously prepared in YNB broth to the final concentration of 2.5  103 
CFU/mL, was added to each well of the compound-containing plates, giving a final standard 
antifungal concentration range of 128 μg/mL to 0.06 μg/mL, and test compound concentration 
range from 256 μg/mL to 0.12 μg/mL. Plates were covered and incubated at 35 C for 24 h. 
Candida albicans MICs were determined by OD530 readings. For Cryptococcus neoformans, 
10 μL of 0.06% resazurin were added to the 24 h incubated plates, and these plates incubated 
for another 3 h. Cryptococcus neoformans MICs were determined by reading OD570-600. 
Inhibition of fungal growth was determined by comparison with the negative growth control 
wells (media only, calculated as an average n = 12) and growth control wells (fungi not treated 
with antifungals, calculated as an average n = 12). The readings above the negative growth 
control average were considered to correspond to fungal growth, therefore correspond to active 
compounds. 
9. Cytotoxicity assay 
The cytotoxicities of compounds on the HEK293 and HepG2 cell lines were measured by 
seeding cells with count of 3000 per well in a clear 384-well plate and final volume of 20 mL 
in the DMEM medium (GIBCO-Invitrogen #11995-073), to which 10% of FBS was added. 
The compounds were tested with a concentration of 10 mM. A 2-fold dilution series was 
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prepared and mixed with the cell suspension directly. Then the cells and compounds were 
incubated for 24 h at 37oC in 5% CO2. After the incubation, 10 µM resazurin (dissolved in 
PBS) was added to each well. The plates were then incubated for 3 hours at 37oC in 5% CO2. 
The fluorescence intensity was read using Polarstar Omega with excitation/emission 560/590 
nm. 
10. Mass spectrometry studies 
Intact mass spectrometry 
For intact mass spectrometry studies, separate samples were prepared for enzyme-only His-
tagged Cryptococcus IMPDH, His-tagged Cryptococcus IMPDH incubated with inhibitor (5d: 
40 µM in DMSO) and His-tagged Cryptococcus IMPDH incubated together with inhibitor 5d 
and different combinations of substrates (IMP and NAD independently and with both IMP and 
NAD). Samples were set up in the same buffer [50 mM Tris-HCl (pH (8.0), 100 mM KCl, 3 
mM EDTA] used for inhibition assays and incubated for 1.5 h on ice (4 % final DMSO 
concentration). A small aliquot (~20 µL) of each sample was prepared for analysis by desalting 
using a C4 ZipTip (Merck Millipore). Samples were eluted from ZipTip with 10 µL of 80% 
ACN/0.1% FA, dried briefly in a speed-vac and resuspended in 20 µL buffer A (1 % ACN/0.1% 
FA). All prepared samples were analysed using an Orbitrap Elite (Thermo) mass spectrometer 
and Dionex Ultimate 3000 nano LC system (Thermo). Samples were first desalted on a C4 
PepMap 300 pre-column (300 µm x 5 mm, 5µm 300 Å) using buffer A (30 µL/min) for 5 min 
and separated on an Acclaim PepMap 300 (75 µm × 150 mm) at a flow rate of 300 nL/min. A 
gradient of 10-98% buffer B over 15 minutes was used, where buffer A was 0.1% formic acid 
in water and buffer B was 80% acetonitrile/0.1% formic acid. The eluted protein was directly 
analysed on an Orbitrap Elite (Thermo) mass spectrometer interfaced with a NanoFlex source. 
The mass spectrometer was operated in positive ion mode using the ion trap analyser.  Source 
parameters included an ion spray voltage of 2 kV, temperature at 275°C, SID = 35V, S-lens = 
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70 V, summed microscans = 10, and intact protein mode on.  MS analysis was performed across 
m/z 600-2000.  Data was deconvoluted using Thermo Protein Deconvolution software™ across 
mass m/z 700-1500. Deconvoluted data was reported as uncharged monoisotopic masses. 
Peptide sequencing 
Proteomics studies were performed for inhibitor-free His-tagged Cryptococcus IMPDH and 
His-tagged Cryptococcus IMPDH incubated with the inhibitor 5d. The preparation of samples 
of Cryptococcus IMPDH with inhibitor 5d and incubation for 1.5 h on ice and incubation at 
room temperature was done in similar manner to samples prepared for intact mass spectrometry 
studies. After incubation, the solution was transferred to Amicon Ultra centrifugal filter (10 
KDa, Millipore) and centrifuged at 4 ℃ to remove any excess unbound inhibitor in the sample. 
The protein was transferred to an Eppendorf tube and trypsin (Promega, V5111) added at a 
concentration of 1:25 (w/w), along with ammonium bicarbonate to a final concentration of 50 
mM. The sample was incubated at 37 ℃ overnight. The protein-only sample was also digested 
with trypsin in parallel. After incubation, a small aliquot (~5 µg) of each sample was taken and 
prepared for analysis by desalting using a C18 ZipTip.  
Digested samples were separated using reverse-phase chromatography on a Dionex Ultimate 
3000 RSLC nano-system. Using a flow rate of 30 µL/min, samples were desalted on a Thermo 
PepMap 100 C18 trap (0.3 × 5 mm, 5 µm) for 5 min, followed by separation on a Acclaim 
PepMap RSLC C18 (150 mm × 75 µm) column at a flow rate of 300 nL/min. A gradient of 10-
50% buffer B over 27 min was used to separate peptides (buffer A corresponded to 1 % 
acetonitrile / 0.1% formic acid and buffer B corresponded to 80% ACN / 0.1% FA). Eluted 
peptides were directly analysed on an Orbitrap Elite mass spectrometer (Thermo) using an NSI 
electrospray interface. Source parameters included a capillary temperature of 275 °C; S-Lens 
RF level at 60%; source voltage of 2 kV and maximum injection times of 200 ms for MS and 
150 ms for MS2. Instrument parameters included an FTMS scan across m/z range 350-1800 at 
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60,000 resolution, followed by information-dependent acquisition of the top 10 peptides across 
m/z 40-1800. Dynamic ion exclusion was employed using a 15-second interval. Charge state 
screening was enabled with rejection of +1 charged ions and monoisotopic precursor selection 
was enabled. 
Data was converted to Mascot generic format (mgf) using the msConvert software 
(ProteoWizard) and searched using Protein Pilot™ v5.0 (Sciex).31,32 A custom database 
containing His-tagged IMPDH was generated.  The unique modification expected for cysteine 
residues (C8H5O2S, +164 Da) was added to the database. 
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